ArticleClinical and experimental nephrology2026
The safety and effectiveness of transcatheter renal arterial embolization with tris-acryl gelatin microspheres in hemodialysis patients with autosomal dominant polycystic kidney disease.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo investigate the safety and effectiveness of transcatheter arterial embolization (TAE) with tris-acryl gelatin microspheres in patients with symptomatic enlarged polycystic kidneys (PCKs). MATERIAL AND
methodsThis prospective study was planned as a safety trial for patients with symptomatic enlarged PCKs who complained of a marked abdominal distention, gastroesophageal reflux, or abdominal pain. We then assessed renal volume reduction and improvement in clinical symptoms as secondary endpoints. The patients after induction of dialysis therapy (urinary volume less than 500 mL per day) were included. Bilateral renal TAE with tris-acryl gelatin microspheres injection followed by metallic coils placement was performed, and adverse events, clinical symptoms, abdominal circumference, blood pressure, dry weight and laboratory data were evaluated at 1, 3, 6 and 12 months after TAE. Each kidney volume was calculated before TAE and at 3, 6 and 12 months after TAE.
resultsSix kidneys of three patients (65-, 58- and 54 years women) were treated. All three patients experienced abdominal pain, vomiting and inflammatory reactions immediately after TAE; however, abdominal pain and vomiting resolved within their hospitalization period, and inflammatory reactions improved during the follow-up period in all patients. Accelerated renal anemia was ameliorated by temporary blood transfusions and increased doses of erythropoiesis-stimulating agent or darbepoetin alpha during dialysis. The mean kidney volume was 3885 mL before TAE and 3025, 2320 and 1832 mL at 3, 6 and 12 months after TAE, respectively.
conclusionRenal TAE with tris-acryl gelatin microspheres is considered a safe and effective treatment for symptomatic enlarged PCKs.
trial registrationThis clinical trial was registered with the University Hospital Medical Information Network (UMIN) under the registration number UMIN000016576.
Indexed as
Identifiers
41028327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.